{"id":924,"date":"2024-07-04T15:45:54","date_gmt":"2024-07-04T15:45:54","guid":{"rendered":"https:\/\/new.samev-dz.com\/?page_id=924"},"modified":"2024-07-04T15:45:54","modified_gmt":"2024-07-04T15:45:54","slug":"communications-presentees-7c2016","status":"publish","type":"page","link":"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/","title":{"rendered":"Communications pr\u00e9sent\u00e9es 7C2016"},"content":{"rendered":"

SEANCE 1: LES ART\u00c8RES DU PATIENT DIAB\u00c9TIQUE<\/strong><\/u><\/h2>\n

Programme de lutte int\u00e9gr\u00e9e contre les facteurs de risque vasculaire. O\u00f9 en sommes-nous ?<\/a>
\nM. Brouri (Alger)<\/strong><\/p>\n

LES ART\u00c8RES DU PATIENT DIAB\u00c9TIQUE: Quel hypolip\u00e9miant ?<\/a>
\nF. Ayad (Oran)<\/strong><\/p>\n

Co 1. L’\u00e9tude Sidi Bel-Abbes Prospecticve Stroke Study (SPSS) : Facteurs pr\u00e9dictifs de la mortalit\u00e9 des accidents vasculaires c\u00e9r\u00e9braux<\/a>
\nM.A. Chami<\/strong>, S.Maamar, F.Arbia-Boudjeltia, W.Zahdour, Z.Nadji, S.Ghlamoun, N.Belhadj, S.T.Hebri, M. Taleb. Service de m\u00e9decine interne, CHU Sidi-Belabas.<\/p>\n

Co 2. Impacts de l\u2019\u00e9ducation th\u00e9rapeutique des patients diab\u00e9tiques de type 2 sur les facteurs de risque cardio-vasculaire.<\/a>
\nN. Lanasri<\/strong>, N.W.Nibouche, A.Chibane, L.Makhlouf, F.Zeraoulia, F.Hansal, H.Gasmi, A.Biad. Service de m\u00e9decine interne, EPH, Ain Taya.<\/p>\n

Co 3. Pr\u00e9valence de l\u2019hypertension art\u00e9rielle dans la commune de Bab El Oued (Alger).<\/a>
\nN. Zanoun<\/strong>, S. Fraga, N. Dekkar , Service de M\u00e9decine du Travail- EPH Rouiba – SEMEP- CHU Bab El Oued.<\/p>\n

SEANCE 2: EXPLORATIONS DES ART\u00c8RES DU PATIENT DIAB\u00c9TIQUE<\/strong><\/u><\/h2>\n

Comment explorer les art\u00e8res du patient diab\u00e9tique ?<\/a>
\nC. Ouarab (Alger)<\/strong><\/p>\n

Interpr\u00e9tation de l\u2019IPS chez le diab\u00e9tique<\/a>
\nP. Lacroix (Limoges)<\/strong><\/p>\n

Echo doppler du patient diab\u00e9tique.<\/a>
\nM. Dadon (Paris)<\/strong><\/p>\n

Co 4. Pr\u00e9valence de l\u2019atteinte carotidienne chez le diab\u00e9tique de type 2 dans la wilaya de Sidi Bel-Abbes et facteurs de risque cardiovasculaire associ\u00e9s.<\/a>
\nS.Maamar<\/strong>, M.Taleb, M.A. Chami. Service de m\u00e9decine interne, CHU Sidi-Belabas.<\/p>\n

Co 5. D\u00e9pistage des l\u00e9sions \u00e0 risque neuro vasculaire par \u00e9cho Doppler des patients diab\u00e9tiques asymptomatiques.<\/a>
\nSlama Baghdad<\/strong>, A.Benamara, T. Sais, A. Benaboud, M. Mefti. H\u00f4pital militaire d\u2019Alger (HCA).<\/p>\n

Co 6. La pression puls\u00e9e aortique du patient NAFLD : \u00e9tude cas-t\u00e9moins.<\/a>
\nS. Taharboucht<\/strong>, A. Hatri, F. Kessal, F. Hamrour, R. Guermaz, S. Zekri, M. Brouri. Service de m\u00e9dicine interne, EPH Elbiar. (Alger)<\/p>\n

Co 7. Pr\u00e9valence de l\u2019atteinte carotidienne ath\u00e9romateuse au cours de la cardiopathie isch\u00e9mique dans un service de cardiologie<\/a>
\nH. Foudad<\/strong>, I. Bouaguel, A.Trichine, R. Merghit , T. Hacini, T. Chelouache , M. Bouame. H\u00f4pital militaire de Constantine (HMRUC), H\u00f4pital militaire d\u2019Alger (HCA).<\/p>\n

SEANCE 3: VASCULARITES ET BIOTH\u00c9RAPIE<\/strong><\/u><\/h2>\n

Crit\u00e8res diagnostiques de la maladie de Takayasu : proposition Alg\u00e9rienne<\/a>
\nA. Hatri (Alger)<\/strong><\/p>\n

Les anti-IL6 dans la maladie de Takayasu : r\u00e9sultats d\u2019une \u00e9tude Alg\u00e9rienne<\/a>
\nF. Hamrour<\/strong><\/p>\n

Le biom\u00e9dicament dans les vascularites : point de vue du clinicien<\/a>
\nN. Dammene-Debbih ( Alger)<\/strong><\/p>\n

Prise en charge th\u00e9rapeutique de la maladie d\u2019Horton : quoi de neuf ?<\/a>
\nM.A. Boudjella<\/strong>\u00a0avec la collaboration des laboratoires Roche.<\/p>\n

Le Biosimilaire : oui ou non ?<\/a>
\nM. Brouri\u00a0<\/strong>R. Guermaz (Alger)<\/p>\n

SEANCE 4: RADIOLOGIE INTERVENTIONNELLE ET CHIRURGIE VASCULAIRE EN 2017<\/strong><\/u><\/h2>\n

Co 8. Pr\u00e9valence et facteurs de risque de l\u2019art\u00e9riopathie oblit\u00e9rante asymptomatique des membres inf\u00e9rieurs d\u00e9pist\u00e9e par la mesure de l\u2019index de pression systolique (IPS) dans un service de cardiologie : Exp\u00e9rience de l\u2019h\u00f4pital militaire de Constantine<\/a>
\nH. Foudad<\/strong>, I. Bouaguel, A. Trichine, R. Merghit, T. Hacini, T.Chelouache. H\u00f4pital militaire universitaire de Constantine.<\/p>\n

Co 9. Morbidit\u00e9 et risque coronarien chez le diab\u00e9tique de type 2 sans art\u00e9riopathie oblit\u00e9rante<\/a>
\nW. Nibouche-hattab<\/strong>, N. Lanasri, F. Zeraoulia, A. Chibane, M. Mesnadi, C. Makhlou\ufb01 ,A. aizel, A. Biad. Service de m\u00e9decine interne, EPH, Ain Taya.<\/p>\n

Co 10: D\u00e9pistage de l\u2019an\u00e9vrysme de l\u2019aorte abdominale lors de l\u2019examen \u00e9cho cardiographique chez les patients \u00e0 risque.<\/a>
\nA. Bouferrouk<\/strong>, S.Boutamine, A Mekarnia. Service de cardiologie. HCA<\/p>\n

Co 12 : Int\u00e9r\u00eat de la TDM dans la dissection aortique.<\/a>
\nR. Boukerroucha<\/strong>, N. Messikh, S. Cherif, S. Bendjaballah, C. Rakouk, A. B. Aziza, K. Bouguerra, F. Aimer, R. Bouharagua , A. Brahami. EHS Mokhtar Djeghri Constantine.<\/p>\n

Co 13 : Traitement par embolisaton des h\u00e9moptysies au cours de la maladie de Beh\u00e7et<\/a>
\nA. Habouchi<\/strong>, C. Aimeur, A. Habba , M. Mouzaoui, A. Maoudj, B. Mansouri. Service de Radiologie, CHU Bab-Eloued.<\/p>\n

SEANCE 5: L\u2019ART\u00c9RIOPATHIE OBLIT\u00c9RANTE DES MEMBRES INF\u00c9RIEURS<\/strong><\/u><\/h2>\n

L\u2019AOMI en Alg\u00e9rie<\/a>
\nS. Zekri (Alger)<\/strong><\/p>\n

L\u2019AOMI en Tunisie<\/a>
\nN. Elleuch (Tunis)<\/strong><\/p>\n

Pied diab\u00e9tique : int\u00e9r\u00eat de l\u2019exploration de la microcirculation<\/a>
\nP. Carpentier(Grenoble)<\/strong><\/p>\n

Traitement m\u00e9dical de l\u2019AOMI<\/a>
\nA. Hatri (Alger)<\/strong>\u00a0avec la collaboration des laboratoires SANOFI.<\/p>\n

SEANCE 6: RADIOLOGIE INTERVENTIONNELLE ET CHIRURGIE VASCULAIRE EN 2017<\/strong><\/u><\/h2>\n

Les endoproth\u00e8ses aortiques : exp\u00e9rience Alg\u00e9rienne<\/a>
\nL. Bouziane<\/strong>, M. N. Bouayed (Oran)<\/p>\n

Techniques et Indications des Proc\u00e9dures Thermiques d\u2019Ablation Endoveineuses<\/a>
\nF. Vin (Paris)<\/strong><\/p>\n

Le laser endoveineux: notre exp\u00e9rience sur une s\u00e9rie de plus de 5OO cas<\/a>
\nR. Belkorissat<\/strong>, M.N Bouayed (Oran)<\/p>\n

Revascularisation du patient diab\u00e9tique: Point de vue du chirurgien vasculaire<\/a>
\nT. Al-Kassar (Beyrouth)<\/strong><\/p>\n

Revascularisation du patient diab\u00e9tique: Point de vue du radiologue interventionnel<\/a>
\nA. Chouiter (Neuch\u00e2tel)<\/strong><\/p>\n

SEANCE 7: ACTUALIT\u00c9 DANS LA MALADIE VEINEUSE THROMBOEMBOLIQUE<\/strong><\/u><\/h2>\n

AOD : pour une meilleure prescription en 2017<\/a>
\nJP. Laroche (Avignon)<\/strong><\/p>\n

La thrombose veineuse c\u00e9r\u00e9brale<\/a>
\nL. Essaadouni (Marrakech)<\/strong><\/p>\n

Cancer et MTEV<\/a>
\nL. Cher\ufb01 (Alger)<\/strong><\/p>\n

La thromboprophylaxie (R\u00e9f\u00e9rentiel SAMEV).<\/a>
\nM. Baba-Ahmed (Alger)<\/strong><\/p>\n

Bilan de thrombophilie : Utile ou Inutile ?<\/a>
\nJP. Laroche (Avignon)<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

SEANCE 1: LES ART\u00c8RES DU PATIENT DIAB\u00c9TIQUE Programme de lutte […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"class_list":["post-924","page","type-page","status-publish","hentry"],"yoast_head":"\nCommunications pr\u00e9sent\u00e9es 7C2016 - Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communications pr\u00e9sent\u00e9es 7C2016 - Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire\" \/>\n<meta property=\"og:description\" content=\"SEANCE 1: LES ART\u00c8RES DU PATIENT DIAB\u00c9TIQUE Programme de lutte [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/\" \/>\n<meta property=\"og:site_name\" content=\"Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/\",\"url\":\"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/\",\"name\":\"Communications pr\u00e9sent\u00e9es 7C2016 - Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire\",\"isPartOf\":{\"@id\":\"https:\/\/new.samev-dz.com\/#website\"},\"datePublished\":\"2024-07-04T15:45:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/new.samev-dz.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communications pr\u00e9sent\u00e9es 7C2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/new.samev-dz.com\/#website\",\"url\":\"https:\/\/new.samev-dz.com\/\",\"name\":\"Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/new.samev-dz.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Communications pr\u00e9sent\u00e9es 7C2016 - Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/","og_locale":"en_US","og_type":"article","og_title":"Communications pr\u00e9sent\u00e9es 7C2016 - Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire","og_description":"SEANCE 1: LES ART\u00c8RES DU PATIENT DIAB\u00c9TIQUE Programme de lutte [...]","og_url":"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/","og_site_name":"Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/","url":"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/","name":"Communications pr\u00e9sent\u00e9es 7C2016 - Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire","isPartOf":{"@id":"https:\/\/new.samev-dz.com\/#website"},"datePublished":"2024-07-04T15:45:54+00:00","breadcrumb":{"@id":"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/new.samev-dz.com\/index.php\/communications-presentees-7c2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/new.samev-dz.com\/"},{"@type":"ListItem","position":2,"name":"Communications pr\u00e9sent\u00e9es 7C2016"}]},{"@type":"WebSite","@id":"https:\/\/new.samev-dz.com\/#website","url":"https:\/\/new.samev-dz.com\/","name":"Soci\u00e9t\u00e9 Alg\u00e9rienne de M\u00e9decine Vasculaire","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/new.samev-dz.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/new.samev-dz.com\/index.php\/wp-json\/wp\/v2\/pages\/924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.samev-dz.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/new.samev-dz.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/new.samev-dz.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/new.samev-dz.com\/index.php\/wp-json\/wp\/v2\/comments?post=924"}],"version-history":[{"count":1,"href":"https:\/\/new.samev-dz.com\/index.php\/wp-json\/wp\/v2\/pages\/924\/revisions"}],"predecessor-version":[{"id":926,"href":"https:\/\/new.samev-dz.com\/index.php\/wp-json\/wp\/v2\/pages\/924\/revisions\/926"}],"wp:attachment":[{"href":"https:\/\/new.samev-dz.com\/index.php\/wp-json\/wp\/v2\/media?parent=924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}